Hemolytic Uremic Syndrome

E. coli, the Shiga toxin source in typical HUS
E. coli, the Shiga toxin source in typical HUS
Fragmented red cells, called schistocytes
Fragmented red cells, called schistocytes

Table of Contents

  1. Overview
  2. Typical HUS (STEC-HUS)
  3. Shiga Toxin Mechanism
  4. Atypical HUS (aHUS)
  5. Clinical Features & Course
  6. Diagnosis
  7. Treatment
  8. HUS vs. TTP
  9. Prognosis & Long-Term Outcomes
  10. Key Research Papers
  11. Featured Videos

Overview

Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA) defined by the triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury (AKI). Unlike its close relative thrombotic thrombocytopenic purpura (TTP), HUS predominantly injures the kidneys — glomerular capillary endothelial cells bear the brunt — rather than the neurological microvasculature.

HUS is the most common cause of acute kidney failure in children in developed countries, and the majority of pediatric cases follow infection with Shiga toxin–producing Escherichia coli (STEC). The recognition that a common foodborne pathogen could trigger catastrophic kidney failure in children transformed food safety regulation and drove landmark basic-science discoveries in complement biology.

Two principal subtypes are distinguished by cause and outcome: typical HUS (STEC-HUS, approximately 90% of cases) is usually self-limited with excellent recovery; atypical HUS (aHUS, approximately 10%) is driven by complement dysregulation, follows a relapsing or progressive course, and before the complement-blocking era ended in dialysis or death for most patients.

Back to Table of Contents

Typical HUS (STEC-HUS)

Typical HUS — also called STEC-HUS, diarrhea-associated HUS, or D+HUS — is caused by Shiga toxin–producing Escherichia coli (STEC). The dominant serotype responsible in the United States and Europe is O157:H7, which produces both Shiga toxin 1 (Stx1) and the more pathogenic Shiga toxin 2 (Stx2). Additional STEC serotypes — O111:H8, O26:H11, O145, and O104:H4 (responsible for the 2011 German outbreak) — are increasingly recognized.

STEC resides in the intestinal tracts of ruminant livestock, particularly cattle, without causing disease in the animal. Human infection follows ingestion of contaminated beef (especially undercooked ground beef), raw leafy vegetables (spinach, romaine lettuce), unpasteurized apple cider or dairy products, contaminated drinking water, or direct animal contact. Person-to-person fecal-oral transmission occurs readily in daycares and households — a feature that amplifies outbreaks because the infectious dose is exceptionally low, sometimes as few as 50–100 organisms.

In US Foodborne Diseases Active Surveillance Network data on 3,464 STEC O157 infections (2000–2006), 218 people (6.3%) developed HUS; the highest share, 15.3%, was in children under 5 years of age — a difference explained in part by the higher density of the Shiga toxin receptor Gb3 (globotriaosylceramide) on pediatric renal endothelial cells relative to adults.

Epidemiology: STEC-HUS affects approximately 2,000–3,000 children per year in the United States, with a peak incidence in summer and early autumn corresponding to increased cattle contact and the season of peak STEC prevalence in the environment.

Back to Table of Contents

Shiga Toxin Mechanism

Shiga toxins belong to the family of AB5 toxins: a single enzymatic A-subunit noncovalently associated with a pentameric B-subunit ring. The B-subunit binds with high affinity to the glycolipid receptor Gb3 (globotriaosylceramide, CD77) on the surface of human cells. Gb3 expression is highest on renal glomerular endothelial cells, renal tubular cells, and in the brain — explaining the tissue tropism of HUS.

The molecular sequence from intestinal colonization to kidney failure proceeds through several steps:

  1. STEC colonizes the large intestine, attaches to the intestinal epithelium, and produces Stx1/Stx2. The toxins cross the intestinal barrier, aided by local mucosal inflammation and cytokine release, and enter the systemic circulation.
  2. Circulating Shiga toxin binds Gb3 on renal glomerular capillary endothelial cells. The AB5 complex is endocytosed via receptor-mediated endocytosis and traffics retrograde through the Golgi to the endoplasmic reticulum.
  3. The A-subunit is proteolytically cleaved into an enzymatically active A1 fragment that depurinates a specific adenine residue on 28S ribosomal RNA — the same mechanism used by ricin. This irreversibly inactivates the ribosome, halting protein synthesis and triggering apoptotic cell death.
  4. Dying endothelial cells in glomerular capillaries retract, exposing the underlying basement membrane to flowing blood. Platelets adhere to this denuded surface, activate, and aggregate — forming platelet microthrombi that occlude glomerular capillary loops.
  5. Occluded glomeruli cannot filter blood. Red blood cells forced through fibrin-platelet thrombi are physically fragmented into schistocytes (helmet cells, triangular forms) — the morphological hallmark of MAHA. Consumed platelets drive thrombocytopenia. Progressive glomerular occlusion leads to oliguria, then anuria, and acute kidney injury.

Importantly, Shiga toxin also activates complement via the alternative pathway and triggers neutrophil-mediated injury — complicating the picture and explaining why complement inhibition has been tried in STEC-HUS. In the first randomized, placebo-controlled trial (100 children, published 2023), eculizumab did not shorten the need for dialysis, but fewer treated children had lasting kidney after-effects at one year (see Treatment).

Why antibiotics are contraindicated in STEC infection: Bactericidal antibiotics (especially fluoroquinolones and trimethoprim-sulfamethoxazole) cause rapid bacterial lysis, releasing a surge of preformed Shiga toxin into the intestinal lumen. Epidemiological studies consistently show higher rates of HUS in children who receive antibiotics for their STEC diarrheal prodrome. Supportive care without antibiotics is the standard of management.

Back to Table of Contents

Atypical HUS (aHUS)

Atypical HUS is a chronic relapsing disease of complement dysregulation rather than an acute infection-triggered event. The complement system, which normally restricts its destructive activation to pathogen surfaces and foreign cells, loses precision on the endothelial cell surface — leading to continuous, low-grade endothelial injury and TMA.

The alternative complement pathway is in constant low-level activation (the "tick-over" mechanism). Under normal conditions, complement factor H (CFH) circulates in plasma and is the principal regulator that recognizes polyanion-rich host cell surfaces (such as endothelium) and dampens C3 activation on those surfaces. Genetic mutations that disable CFH — or other regulators — allow the alternative pathway to amplify unchecked on the endothelium:

Approximately 30–40% of aHUS cases have no identified mutation despite comprehensive genetic panel testing — reflecting incomplete genetic discovery, variants of uncertain significance, or uncharacterized regulators. Genetic testing nevertheless has major implications for treatment, prognosis, and donor kidney selection for transplant.

Triggers for clinical episodes in genetically predisposed individuals include infections (especially upper respiratory tract infections in children — the "two-hit" model: predisposing mutation + trigger), pregnancy (particularly postpartum, when complement activation is highest), surgery, organ transplantation, and certain drugs (tacrolimus, bevacizumab, quinine, oral contraceptive pills).

Back to Table of Contents

Clinical Features & Course

Typical HUS (STEC-HUS): The illness evolves in two phases separated by roughly 5–10 days:

  1. Prodromal diarrheal phase (days 1–5): crampy abdominal pain and watery diarrhea that becomes grossly bloody in 80–90% of cases — the "bloody diarrhea" that prompts medical evaluation. Vomiting is common. Fever is often absent or low-grade early, distinguishing STEC from other bacterial causes of bloody diarrhea. The child may appear well between cramps.
  2. HUS phase (days 5–15): as diarrhea improves, the TMA triad emerges — pale (hemolytic anemia), petechiae or purpura (thrombocytopenia), and reduced urine output (acute kidney injury). Hypertension is nearly universal once acute kidney injury develops. Edema from fluid overload and hypoalbuminemia accumulates.

Extrarenal complications in STEC-HUS:

Atypical HUS: presentation is more insidious and variable. Acute kidney injury is often the dominant presenting feature, without a clear infectious prodrome. Episodes may be triggered by an identifiable event (infection, pregnancy) or occur spontaneously. Before eculizumab, a 2011 review reported that 2–10% of people with aHUS died and one third progressed to end-stage renal disease (ESRD) at the first episode, and half had relapses; in the worst subgroup, factor H–associated aHUS, mortality could reach 20% and 50% of survivors did not recover kidney function. Recurrence after kidney transplant was frequent (50–90% depending on genetic mutation), destroying transplanted kidneys.

Back to Table of Contents

Diagnosis

The diagnostic evaluation serves two goals: confirm TMA and identify its cause (because the cause determines whether antibiotics are dangerous, whether eculizumab is indicated, and whether kidney transplant is safe).

Initial laboratory evaluation:

STEC-specific testing:

aHUS evaluation: when STEC testing is negative and TTP (ADAMTS13) has been excluded, the evaluation includes:

Back to Table of Contents

Treatment

Typical HUS (STEC-HUS) — supportive care:

Atypical HUS — eculizumab and ravulizumab:

Eculizumab is a monoclonal antibody that binds complement C5 and blocks its cleavage into C5a (the anaphylatoxin that amplifies inflammation) and C5b (the initiating component of the membrane attack complex). By blocking terminal complement activation, eculizumab halts the endothelial injury cycle in aHUS.

Ravulizumab — a longer-acting anti-C5 antibody (half-life ~50 days vs. ~12 days for eculizumab) approved for aHUS in 2019; allows 8-week dosing intervals after induction, reducing the burden of frequent infusions while maintaining equivalent efficacy.

Two-year results from the two phase 3 ravulizumab trials (published 2024; 86 patients in the efficacy analysis) reported a complete response — platelet count and LDH back to normal and serum creatinine improved by at least 25% — in 61% of adults and 90% of children who had not had a complement blocker before. Infusions were given every 4–8 weeks depending on body weight, most side effects occurred in the first 26 weeks, and no meningococcal infections were reported. These were single-arm studies with no comparison group.

Eculizumab in STEC-HUS: in the first randomized, placebo-controlled trial (published 2023), 100 children with STEC-HUS received eculizumab or placebo for 4 weeks. The share needing dialysis for less than 48 hours did not differ significantly (38% with eculizumab vs. 48% with placebo), nor did the blood or extrarenal course, but at one year fewer children in the eculizumab group had kidney after-effects (43.5% vs. 64.4%). The authors wrote that larger studies would be needed; supportive care remains the standard for STEC-HUS.

Plasma exchange (PEX): used empirically before the cause is confirmed (to treat possible TTP while awaiting ADAMTS13) or as a bridge in aHUS when eculizumab is not immediately available. PEX removes anti-CFH autoantibodies and replenishes CFH protein in CFH-mutation HUS. Its role in aHUS has been largely supplanted by complement blockade.

Kidney transplantation: major complication in aHUS before eculizumab — recurrence in the transplanted kidney was common (50–90% in CFH-mutation aHUS, leading to allograft loss in most). With prophylactic perioperative eculizumab continued post-transplant, outcomes have dramatically improved and are now comparable to other kidney diseases.

Back to Table of Contents

HUS vs. TTP

Both HUS and TTP are thrombotic microangiopathies presenting with MAHA and thrombocytopenia, and they were historically confused under the same umbrella. Distinguishing them is critical because treatment differs fundamentally:

In clinical practice, when a patient presents with TMA and the cause is unclear, ADAMTS13 testing is sent immediately and plasma exchange is often started empirically to treat possible TTP while awaiting results. Once ADAMTS13 returns normal and STEC testing is positive, antibiotics are withheld and supportive care follows.

Back to Table of Contents

Prognosis & Long-Term Outcomes

STEC-HUS: overall prognosis is favorable with modern supportive care. Acute mortality is under 5% in contemporary series. Approximately 65–85% of children recover normal renal function by 1 year; however, long-term sequelae are more common than once believed:

In US surveillance of 770 children hospitalized with diarrhea-associated HUS in 10 states (1997–2012), 56.5% needed dialysis, 92.6% needed a transfusion and 2.9% died; 7.3% still needed dialysis at discharge. A higher white-cell count, a higher hematocrit and a respiratory infection in the 3 weeks before diagnosis were linked with a greater chance of death in hospital.

Predictors of worse renal outcome include: prolonged oligoanuria (>10 days), need for dialysis, initial white blood cell count >20,000/µL (marker of severe toxin-mediated inflammation), and neurological involvement.

aHUS: pre-eculizumab era — serious (2–10% died and one third reached ESRD at the first episode; in factor H–associated aHUS, mortality up to 20% and half of survivors without kidney recovery; frequent graft loss in transplant). With early eculizumab, the majority of patients recover renal function; long-term continuous treatment is typically required (particularly for CFH mutations) to prevent relapse. Research has looked at whether treatment can safely be stopped. In the French STOPECU study (55 children and adults, published 2021), eculizumab was stopped in a strategy based on complement genetics; 13 patients (23%) relapsed, with a higher risk in women and in carriers of a rare complement gene variant, and 11 of the 13 regained their earlier kidney function after restarting. The authors concluded that genetics-based discontinuation is reasonable and safe.

Back to Table of Contents

Key Research Papers

  1. Tarr PI et al. "Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome." Lancet. 2005;365(9464):1073–86. — PubMed PMID: 15781103
  2. Noris M, Remuzzi G. "Atypical hemolytic-uremic syndrome." N Engl J Med. 2009;361(17):1676–87. — PubMed PMID: 19846853
  3. Legendre CM et al. "Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome." N Engl J Med. 2013;368(23):2169–81. — PubMed PMID: 23738544
  4. Karpman D, Sartz L, Johnson S. "Pathophysiology of typical hemolytic uremic syndrome." Semin Thromb Hemost. 2010;36(6):575–85. — PubMed PMID: 20865634
  5. Frank C et al. "Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany." N Engl J Med. 2011;365(19):1771–80. — PubMed PMID: 21696328
  6. Loirat C, Frémeaux-Bacchi V. "Atypical hemolytic uremic syndrome." Orphanet J Rare Dis. 2011;6:60. — PubMed PMID: 21902819
  7. Wong CS et al. "The risk of hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections." N Engl J Med. 2000;342(26):1930–6. — PubMed PMID: 10874060
  8. Fremeaux-Bacchi V et al. "Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults." Clin J Am Soc Nephrol. 2013;8(4):554–62. — PubMed PMID: 23307876
  9. Nester CM et al. "Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome." Clin J Am Soc Nephrol. 2011;6(6):1488–94. — Search PubMed
  10. Mache CJ et al. "Complement inhibitor eculizumab in atypical hemolytic uremic syndrome." Clin J Am Soc Nephrol. 2009;4(8):1312–6. — PubMed PMID: 19556379
  11. Garg AX et al. "Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression." JAMA. 2003;290(10):1360–70. — PubMed PMID: 12966129
  12. Gould LH, Demma L, Jones TF, et al. "Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000-2006." Clin Infect Dis. 2009;49(10):1480–5. — PubMed PMID: 19827953
  13. Mody RK, Gu W, Griffin PM, et al. "Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death." J Pediatr. 2015;166(4):1022–9. — PubMed PMID: 25661408
  14. Fakhouri F, Fila M, Hummel A, et al. "Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study." Blood. 2021;137(18):2438–49. — PubMed PMID: 33270832
  15. Garnier A, Brochard K, Kwon T, et al. "Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial." J Am Soc Nephrol. 2023;34(9):1561–73. — PubMed PMID: 37303085
  16. Dixon BP, Kavanagh D, Aris ADM, et al. "Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials." Kidney Med. 2024;6(8):100855. — PubMed PMID: 39105067

Back to Table of Contents

Connections

Back to Table of Contents